Article

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates

2021-08-16

Abstract excerpt

The CVnCoV (CureVac) mRNA vaccine for SARS-CoV-2 has recently been evaluated in a phase 2b/3 efficacy trial in humans. CV2CoV is a second-generation mRNA vaccine with optimized non-coding regions and enhanced antigen expression. Here we report a head-to-head study of the immunogenicity and protective efficacy of CVnCoV and CV2CoV in nonhuman primates. We immunized 18 cynomolgus macaques with two doses of 12 ug of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 97eb6cda-d2cc-5ad5-8de4-629d4428a368
DOI: 10.1101/2021.08.13.456316

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman PrimatesDOI 10.1101/2021.08.13.456316Read

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccineSemantic proximity Read

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodentsSemantic proximity Read

Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variantsSemantic proximity Read

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccineSemantic proximity Read

Challenges and developments in universal vaccine design against SARS-CoV-2 variantsSemantic proximity Read

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studiesSemantic proximity Read

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody ResponsesSemantic proximity Read

mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognitionSemantic proximity Read

Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variantSemantic proximity Read

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read

Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variantsSemantic proximity Read

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2Semantic proximity Read